Study Links E-Cigarette Bans to Increased Cigarette Sales

Apr.08.2022
Study Links E-Cigarette Bans to Increased Cigarette Sales
A new study suggests that state-level e-cigarette bans are associated with increased cigarette sales.

According to foreign media reports, a new study suggests that a national ban on e-cigarettes is linked to an increase in cigarette sales. The study, published in the scientific journal "Health Affairs," adds to mounting evidence that banning the sale of e-cigarettes may lead more people to revert back to smoking, which is less safe than using nicotine alternatives.

 

During a three-month study, it was found that an additional 3.4 million cigarette packs were sold through convenience stores across three states.

 

Researchers have used state-level cigarette sales data to discover that Massachusetts, which has implemented a complete ban on nicotine e-cigarettes, has seen a 7.5% increase in per capita cigarette sales compared to expectations. Rhode Island and Washington, which have enacted bans on non-tobacco flavored nicotine e-cigarettes, have an average estimated increase of 4.6% in per capita cigarette sales compared to expectations. Based on actual and estimated cigarette sales, the researchers suggest that an additional 3.4 million cigarette packs were sold in convenience stores across the three states during the three-month study period following the implementation of their respective bans.

 

The study was sponsored by Juul Labs, but has had little impact thus far, possibly due to the belief among many in the tobacco control field that research funded by the industry is biased. This debate may stem from decades of data suppression by big tobacco companies, which has recently resurfaced. For example, the Society for Research on Nicotine and Tobacco (SRNT) now explicitly prohibits industry-sponsored speakers from presenting at its conferences, a move that has led to resignations and condemnation of current tobacco control as "anti-scientific".

 

Researchers examined data from the fall of 2019, when legislators began paying attention to a series of mysterious lung diseases referred to as EVALI, which were quickly associated with e-cigarettes by politicians. Although by November 2019, the Centers for Disease Control and Prevention (CDC) had attributed most cases to contaminated illegal THC cartridges, state governments still stirred up panic and sought emergency bans, which in some cases became permanent.

 

In response to the EVALI outbreak, Massachusetts instituted an emergency ban on all nicotine e-cigarettes starting on September 24, 2019. Rhode Island and Washington followed suit, implementing four-month emergency bans on non-tobacco flavored nicotine e-cigarettes on October 4, 2019, and October 10, 2019, respectively. Massachusetts has since permanently banned the sale of flavored e-cigarette products, including menthol, while Rhode Island and Washington's emergency bans have expired, though a permanent flavor ban remains on the table.

 

Previous research has found similar results to those presented in health value papers.

 

The use of nicotine has not been linked to any diagnosis of EVALI in the field of medicine, but misinformation continues to spread. Under the guidance of sensationalist reporting by policymakers and the media, concerns over the rates of youth vaping have directly sparked fears over deadly vaping products. Misleading information is simple: youth are using e-cigarettes and, in some cases, dying from them. Over two years have passed since the outbreak, and the Centers for Disease Control and Prevention (CDC) in the US have yet to release any formal correction stating that nicotine e-cigarettes are not associated with lung injuries.

 

Previous research has yielded similar results to the findings of a health-focused paper. Co-authors from Boston University published an article in the Harm Reduction Journal indicating that misunderstandings surrounding EVALI (e-cigarette or vaping product use-associated lung injury) – which led to a ban in Massachusetts – appeared to have increased cigarette consumption across Boston. Moreover, Dr. Abigail Friedman from Yale University found in JAMA Pediatrics that after San Francisco banned flavored e-cigarettes and tobacco products, high schoolers in the city were more likely to smoke than their peers in other similar districts across the US.

 

(Source: Filter)

 

Restrictions on vaping products may have unintended consequences, including an increase in cigarette sales. While policymakers have focused on limiting access to e-cigarettes, they may inadvertently be pushing consumers back to traditional tobacco products. This is especially problematic given the well-documented health risks associated with smoking. It remains to be seen whether tighter regulations on vaping will have the intended impact of reducing nicotine addiction overall.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
Philip Morris International's IQOS has extended its partnership with electronic-music event brand ZAMNA to Spain, setting up a House of IQOS at ZAMNA Madrid. Vogue España and Time Out Madrid subsequently published branded content clearly labeled as collaborations with IQOS. PMI has also expanded its company-owned IQOS boutique network in Spain to seven cities this year. The company says IQOS's adjusted heated-tobacco market share in Europe reached 12.6% in the first quarter of 2026, with Spain among its stronger-performing European markets.
Sep.20
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Special Report | Vape bans and tougher rules: the South Caucasus takes different paths
Special Report | Vape bans and tougher rules: the South Caucasus takes different paths
Azerbaijan's sweeping e-cigarette ban has raised concerns over enforcement errors and the emergence of illicit sales, while neighboring Armenia is tightening technical rules and preparing higher excise taxes. Georgia, meanwhile, has resisted calls for broader vape restrictions and introduced preferential taxes for some domestically produced cigarettes. The divergent approaches across the South Caucasus highlight a regional policy dilemma: how to curb nicotine use and protect public health without encouraging black markets or creating unintended economic consequences for businesses and consumers.
Nov.03
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22